CompletedNot Applicable

Diagnostic and Therapeutic Approaches to Hyperinflation and Small Airway Disease in COPD

Germany26 participantsStarted 2017-10-02

Plain-language summary

Current guideline-based criteria defining COPD do not meet the challenges set by the complex pathophysiology of the disease. Hyperinflation and affection of the small airways are two components that are not represented in current diagnostic concepts and may relate to early stages of the disease. Moreover, optimal therapeutic interventions in patients with these distinct features remain unclear. The investigators therefore aimed to evaluate novel or not widely used diagnostic approaches for the detection and initiating therapeutic strategies in early stage COPD within the GOLD recommendations.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * known or first diagnosis of COPD * lung function testing consistent with hyperinflation or peripheral obstruction * emphysema in imaging * symptoms (dyspnea, cough, sputum) and risk factors (\>= 10 pack years) * indication for bronchodilator therapy Exclusion Criteria: * GOLD stages 3 and 4 (spirometric) * indication for dual bronchodilator therapy, triple therapy or inhaled steroid * contraindication for cardiopulmonary exercise testing * unwilling to participate

What they're measuring

residual volume

Timeframe: 8 weeks

D5-20

Timeframe: 8 weeks

LCI

Timeframe: 8 weeks

Trial details

NCT IDNCT03287921

SponsorUniversitätsmedizin Mannheim

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-11-30

View on ClinicalTrials.gov More COPD trials